The new oral anticoagulants

Clinical Medicine, Journal of the Royal College of Physicians of London

Volumn 11, Issue 5, 2011, Pages 467-469

  Breen, K A ^a   Hunt, B J ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACENOCOUMAROL; AMIODARONE; ANTICOAGULANT AGENT; ANTIVITAMIN K; APIXABAN; ATAZANAVIR; CYTOCHROME P450 3A4; DABIGATRAN; DABIGATRAN ETEXILATE; DALTEPARIN; EDOXABAN; ENOXAPARIN; FONDAPARINUX; HEPARIN; KETOCONAZOLE; LOW MOLECULAR WEIGHT HEPARIN; NONSTEROID ANTIINFLAMMATORY AGENT; RITONAVIR; RIVAROXABAN; VERAPAMIL; WARFARIN; XIMELAGATRAN;

ACUTE CORONARY SYNDROME; ANTICOAGULANT THERAPY; BLEEDING; CEREBROVASCULAR ACCIDENT; CONFERENCE PAPER; EMBOLISM; GASTROINTESTINAL SYMPTOM; HEART ATRIUM FIBRILLATION; HIP ARTHROPLASTY; HUMAN; KNEE ARTHROPLASTY; KNEE SURGERY; RECURRENT DISEASE; STROKE; VENOUS THROMBOEMBOLISM;

EID: 80054891473     PISSN: 14702118     EISSN: 14734893     Source Type: Journal    
DOI: 10.7861/clinmedicine.11-5-467     Document Type: Conference Paper

References (17)

1. Yusuf S, Mehta SR, Chrolavicius S et al.; OASIS-6 Trial Group. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA 2006;295:1519-30.
2. Fitzmaurice, DA Gardiner C, Kitchen S et al.; British Society of Haematology Taskforce for Haemostasis and Thrombosis. An evidence-based review and guidelines for patient self-testing and management of oral anticoagulation. Br J Haematol 2005;131:156-65. (Pubitemid 43899680)
3. Gustafsson D, Elg M. The pharmacodynamics and pharmacokinetics of the oral direct thrombin inhibitor ximelagatran and its active metabolite melagatran: a mini-review. Thromb Res 2003;109(Suppl 1):S9-15.
4. Eriksson BI, Dahl OE, Rosencher N et al. RE-NOVATE Study Group. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, doubleblind, non-inferiority trial. Lancet 2007;370:949-56. (Pubitemid 47393577)
5. Eriksson BI Dahl OE, Rosencher N et al.; RE-MODEL Study Group. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 2007;5:2178-85. (Pubitemid 47617868)
6. Ginsberg JS, Davidson BL, Comp PC et al. RE-MOBILIZE Writing Committee. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty 2009;24:1-9.
7. Connolly SJ Ezekowitz MD, Yusuf S et al.; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-51.
8. Wallentin L, Yusuf S, Ezekowitz MD et al.; RE-LY investigators. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet 2010;376:975-83.
9. Schulman S, Kearon C, Kakkar AK et al. RE-COVER Study Group. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009;361:2342-52.
10. Eriksson BI, Borris LC, Friedman RJ et al.; RECORD1 Study Group. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008;358:2765-75. (Pubitemid 351930851)
11. Kakkar AK, Brenner B, Dahl OE et al.; RECORD2 Investigators. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 2008; 372:31-9.
12. Lassen MR, Ageno W, Borris LC et al.; RECORD3 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008;358:2776-86. (Pubitemid 351930852)
13. Turpie AG, Lassen MR, Davidson BL et al.; RECORD4 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet 2009;373:1673-80.
14. Lassen MR, Raskob GE, Gallus A et al. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med 2009;361:594-604.
15. Lassen MR, Raskob GE, Gallus A et al.; ADVANCE-2 investigators. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet 2010;375:807-15.
16. Raskob G, Cohen AT, Eriksson BI et al. Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study. Thromb Haemost 2010;104:642-9.
17. Fuji T, Fujita S, Tachibana S, Kawai Y. A dose-ranging study evaluating the oral factor Xa inhibitor edoxaban for the prevention of venous thromboembolism in patients undergoing total knee arthroplasty. J Thromb Haemost 2010;8:2458-68.